Skip to main content
Top
Published in: Clinical Rheumatology 5/2017

01-05-2017 | Brief Report

Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis

Authors: Jesus Giovanny Ballesteros Muñoz, Rodrigo B. Giraldo, Ana M. Santos, Juan Manuel Bello-Gualteros, Juan C. Rueda, Eugenia-Lucia Saldarriaga, Jose-Ignacio Angarita, Sofia Arias-Correal, Andres Y. Vasquez, John Londono

Published in: Clinical Rheumatology | Issue 5/2017

Login to get access

Abstract

The objective of this study is to correlate the patient-driven tool Routine Assessment of Patient Index Data 3 (RAPID-3) with other common tools used in daily practice to measure disease activity in rheumatoid arthritis (RA).One hundred nineteen RA patients according to 1987 American College of Rheumatology criteria who consecutively attended a RA outpatient clinic between August and December 2015 were evaluated. Data was stored in an electronic form that included demographic information, comorbidities, concomitant medication, and laboratory results. The disease activity was determined by tender and swollen joint count, pain and disease activity visual analog scales (VAS), disease activity score 28 (DAS28), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), and multidimensional health assessment questionnaire (MDHAQ). Correlations between RAPID-3 and other disease activity tools were assessed. Mean age was 61 ± 13.8 years with a median disease duration of 14 years (IQR 5–21), 77% were females. Median scores were MDHAQ 0.5 (IQR 0.1–1.2), DAS 28 3.8 (IQR 2.7–5.1), and RAPID-3 12.3 (IQR 6–19). A strong correlation was obtained between RAPID-3 and DAS 28 (r 0.719, p < 0.001), CDAI (r 0.752, p < 0.001), and SDAI (r 0.758, p < 0.001). RAPID-3 had a high correlation with tools regularly used for disease activity assessment of RA patients in daily practice. The ease of its application favors routine use as it does not require laboratory results and joint counts.
Literature
1.
go back to reference Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O’Dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64:640–647. doi:10.1002/acr.21649 CrossRef Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O’Dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64:640–647. doi:10.​1002/​acr.​21649 CrossRef
2.
go back to reference Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S et al (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573–586. doi:10.1002/art.30129 CrossRefPubMedPubMedCentral Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S et al (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573–586. doi:10.​1002/​art.​30129 CrossRefPubMedPubMedCentral
3.
go back to reference Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509. doi:10.1136/annrheumdis-2013-204573 CrossRefPubMed Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509. doi:10.​1136/​annrheumdis-2013-204573 CrossRefPubMed
5.
go back to reference Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet (London, England) 364:263–269. doi:10.1016/S0140-6736(04)16676-2 CrossRef Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet (London, England) 364:263–269. doi:10.​1016/​S0140-6736(04)16676-2 CrossRef
6.
go back to reference Taylor DA (1937) Table for the degree of involvement in chronic arthritis. Can Med Assoc J 36:608–610 Available at: Accessed June 27, 2016PubMedPubMedCentral Taylor DA (1937) Table for the degree of involvement in chronic arthritis. Can Med Assoc J 36:608–610 Available at: Accessed June 27, 2016PubMedPubMedCentral
14.
go back to reference Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 38:44–48. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7818570 Accessed June 27, 2016 Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 38:44–48. Available at: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​7818570 Accessed June 27, 2016
15.
go back to reference van der Heijde DM, van ’t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis (1990) 49:916–920. doi:10.1136/ard.49.11.916 van der Heijde DM, van ’t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis (1990) 49:916–920. doi:10.​1136/​ard.​49.​11.​916
18.
go back to reference Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 36:729–740 Available at: http://www.ncbi.nlm.nih.gov/pubmed/8507213 Accessed June 27, 2016CrossRefPubMed Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 36:729–740 Available at: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​8507213 Accessed June 27, 2016CrossRefPubMed
19.
go back to reference Anderson JK, Zimmerman L, Caplan L, Michaud K (2011) Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Cl. Arthritis Care Res (Hoboken) 63:S14–S36. doi:10.1002/acr.20621 CrossRef Anderson JK, Zimmerman L, Caplan L, Michaud K (2011) Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Cl. Arthritis Care Res (Hoboken) 63:S14–S36. doi:10.​1002/​acr.​20621 CrossRef
21.
go back to reference Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 36:1387–1390. doi:10.3899/jrheum.080770 CrossRefPubMed Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 36:1387–1390. doi:10.​3899/​jrheum.​080770 CrossRefPubMed
22.
go back to reference Pincus T, Yazici Y, Sokka T, Goldsmith CH, Smythe HA, Helewa A, Riel PLCM van, Felson DT, Anderson JJ, Boers M, et al. Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol (2007) 21:601–628. doi:10.1016/j.berh.2007.02.007 Pincus T, Yazici Y, Sokka T, Goldsmith CH, Smythe HA, Helewa A, Riel PLCM van, Felson DT, Anderson JJ, Boers M, et al. Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol (2007) 21:601–628. doi:10.​1016/​j.​berh.​2007.​02.​007
24.
go back to reference Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796–R806. doi:10.1186/ar1740 CrossRefPubMedPubMedCentral Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796–R806. doi:10.​1186/​ar1740 CrossRefPubMedPubMedCentral
25.
go back to reference Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, Santed R, Valderas JM, Ribera A, Domingo-Salvany A et al (2005) El Cuestionario de Salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit 19:135–150. doi:10.1157/13074369 CrossRefPubMed Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, Santed R, Valderas JM, Ribera A, Domingo-Salvany A et al (2005) El Cuestionario de Salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit 19:135–150. doi:10.​1157/​13074369 CrossRefPubMed
26.
go back to reference Amaya-Amaya J, Botello-Corzo D, Calixto O-J, Calderón-Rojas R, Domínguez A-M, Cruz-Tapias P, Montoya-Ortiz G, Mantilla R-D, Anaya J-M, Rojas-Villarraga A (2012) Usefulness of patients-reported outcomes in rheumatoid arthritis focus group. Arthritis 2012:935187. doi:10.1155/2012/935187 CrossRefPubMedPubMedCentral Amaya-Amaya J, Botello-Corzo D, Calixto O-J, Calderón-Rojas R, Domínguez A-M, Cruz-Tapias P, Montoya-Ortiz G, Mantilla R-D, Anaya J-M, Rojas-Villarraga A (2012) Usefulness of patients-reported outcomes in rheumatoid arthritis focus group. Arthritis 2012:935187. doi:10.​1155/​2012/​935187 CrossRefPubMedPubMedCentral
27.
go back to reference Singh H, Gupta V, Ray S, Kumar H, Talapatra P, Kaur M, Kumar S, Arya S, Mathur R, Ghangas N (2012) Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience. Clin Rheumatol 31:1663–1669. doi:10.1007/s10067-012-2070-9 CrossRefPubMed Singh H, Gupta V, Ray S, Kumar H, Talapatra P, Kaur M, Kumar S, Arya S, Mathur R, Ghangas N (2012) Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience. Clin Rheumatol 31:1663–1669. doi:10.​1007/​s10067-012-2070-9 CrossRefPubMed
28.
go back to reference Pincus T, Yazici Y, Sokka T, Waaler E, Rose HM, Ragan C, Pearce E, al. et, Hargraves MM, Richmond H, et al. Complexities in assessment of rheumatoid arthritis: absence of a single gold standard measure. Rheum Dis Clin N Am (2009) 35:687–697, doi:10.1016/j.rdc.2009.10.002 Pincus T, Yazici Y, Sokka T, Waaler E, Rose HM, Ragan C, Pearce E, al. et, Hargraves MM, Richmond H, et al. Complexities in assessment of rheumatoid arthritis: absence of a single gold standard measure. Rheum Dis Clin N Am (2009) 35:687–697, doi:10.​1016/​j.​rdc.​2009.​10.​002
31.
go back to reference Belmonte Serrano MÁ (2008) ¿Es la puntuación DAS28 el método más adecuado para estimar la actividad de la artritis reumatoide? Consideracionens clinimétricas y escenarios de simulación. Reumatol Clínica 4:183–190. doi:10.1016/S1699-258X(08)72462-8 CrossRef Belmonte Serrano MÁ (2008) ¿Es la puntuación DAS28 el método más adecuado para estimar la actividad de la artritis reumatoide? Consideracionens clinimétricas y escenarios de simulación. Reumatol Clínica 4:183–190. doi:10.​1016/​S1699-258X(08)72462-8 CrossRef
32.
go back to reference Pincus T, Swearingen CJ, Bergman M, Yazici Y (2008) RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 35:2136–2147 Available at: http://www.ncbi.nlm.nih.gov/pubmed/18793006 Accessed June 27, 2016CrossRefPubMed Pincus T, Swearingen CJ, Bergman M, Yazici Y (2008) RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 35:2136–2147 Available at: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18793006 Accessed June 27, 2016CrossRefPubMed
33.
go back to reference Pincus T, Swearingen CJCJ, Bergman MJMJ, Colglazier CLL, Kaell ATAT, Kunath AMAM, Siegel ELEL, Yazici Y (2010) RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than. Arthritis Care Res (Hoboken) 62:181–189. doi:10.1002/acr.20066 CrossRef Pincus T, Swearingen CJCJ, Bergman MJMJ, Colglazier CLL, Kaell ATAT, Kunath AMAM, Siegel ELEL, Yazici Y (2010) RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than. Arthritis Care Res (Hoboken) 62:181–189. doi:10.​1002/​acr.​20066 CrossRef
35.
go back to reference Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R (2008) An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 47:345–349. doi:10.1093/rheumatology/kem364 CrossRef Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R (2008) An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 47:345–349. doi:10.​1093/​rheumatology/​kem364 CrossRef
Metadata
Title
Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis
Authors
Jesus Giovanny Ballesteros Muñoz
Rodrigo B. Giraldo
Ana M. Santos
Juan Manuel Bello-Gualteros
Juan C. Rueda
Eugenia-Lucia Saldarriaga
Jose-Ignacio Angarita
Sofia Arias-Correal
Andres Y. Vasquez
John Londono
Publication date
01-05-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 5/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3521-5

Other articles of this Issue 5/2017

Clinical Rheumatology 5/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine